Trial Summary
What is the purpose of this trial?
This study will evaluate the pharmacokinetics and pharmacodynamics of vaporized b-myrcene and THC administered via inhalation.
Research Team
Ryan Vandrey, PhD
Principal Investigator
Johns Hopkins University
Eligibility Criteria
This trial is for adults aged 18-55 in good health with a BMI of 18-36 kg/m2. Participants must not be pregnant, nursing, or have high blood pressure; they should test negative for drugs (except cannabis) and demonstrate cognitive competency. Those using certain medications or with significant medical/psychiatric conditions are excluded.Inclusion Criteria
Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg
My overall health is good, as confirmed by recent medical exams and tests.
Have a body mass index (BMI) in the range of 18 to 36 kg/m2
See 9 more
Exclusion Criteria
I have anemia or I donated blood in the last 30 days.
I am not on medication that affects the study, except for birth control.
I haven't taken any over-the-counter drugs, supplements, or vitamins in the last 14 days that could affect the study.
See 4 more
Treatment Details
Interventions
- Beta-Myrcene (Terpene)
- THC (Cannabinoid)
Trial OverviewThe study investigates the effects of vaporized THC and Beta-Myrcene on participants compared to a placebo. It aims to understand how these substances are processed by the body and their impact when inhaled.
Participant Groups
9Treatment groups
Experimental Treatment
Placebo Group
Group I: Vaporized low beta-myrceneExperimental Treatment1 Intervention
2mg of vaporized beta-myrcene
Group II: Vaporized low THC and low beta-myrceneExperimental Treatment2 Interventions
15mg vaporized THC with 2mg vaporized beta-myrcene
Group III: Vaporized low THC and high beta-myrceneExperimental Treatment2 Interventions
15mg vaporized THC with 9mg vaporized beta-myrcene
Group IV: Vaporized low THC aloneExperimental Treatment1 Intervention
15mg of vaporized pure THC
Group V: Vaporized high beta-myrceneExperimental Treatment1 Intervention
9mg of vaporized beta-myrcene
Group VI: Vaporized high THC and low beta-myrceneExperimental Treatment2 Interventions
30mg vaporized THC with 2mg vaporized beta-myrcene
Group VII: Vaporized high THC and high beta-myrceneExperimental Treatment2 Interventions
30mg vaporized THC with 9mg vaporized beta-myrcene
Group VIII: Vaporized high THC aloneExperimental Treatment1 Intervention
30mg of vaporized pure THC
Group IX: PlaceboPlacebo Group1 Intervention
Placebo (ambient air)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Johns Hopkins University
Lead Sponsor
Trials
2,366
Recruited
15,160,000+
National Institute on Drug Abuse (NIDA)
Collaborator
Trials
2,658
Recruited
3,409,000+